Thread by @mmPharmD

Did you make it into the hottest midday session, Seeing Red: Managing Multidrug Resistant Gram-Negative Infections? Easily met room capacity!

@ProCEhealth Richard Lewis introducing @ErinMcCreary and @OncIDPharmd (Sam Aitken)

@ASHPOfficial #ASHP19

Why is this talk titled "seeing red"? Not because you look like this guy ➡️🤬 but because of the micro report!

Man, I love me a witty title! 👏🏻

So many good slides here! Visual simplification of methods of GNR resistance. The boxed ones are most important in GNRs. #ASHP19 #SIDPEC

Which drugs are affected by which mechanism? Don't worry, Sam's got you covered 😎

Most BL resistance in GNRs is driven by beta-lactamases. #ASHP19 #SIDPEC

But Sam, what beta-lactamases are there? And which antibiotics do they affect?

So glad you asked! 👇🏻 #ASHP19 #SIDPEC

This is such a beautiful slide 😭 Sam, I may have to steal it very soon.

Overview of recent FDA approval for new antobiotics. #ASHP19 #SIDPEC

The @CDCgov @CDC_NCEZID and @CDDEP have great visuals and rates of CRE HOWEVER it's important to know your local epidemiology. Here is a great example why #ASHP19 #SIDPEC

Two beautiful slides summarizing the roles of CAZ/AVI and MER/VAB in CRE infections. #ASHP19 #SIDPEC

Careful! These drugs are NOT interchangeable and you need to know your problem pathogens to decide which need to be on formulary.

Wonderful visual of the mortality benefit of the newer agents against "best available therapy" aka a hot mess of old, toxic, ineffective antibiotic combinations (colistin, aminoglycosides, tigecycline, etc).

Why 👏🏻 are 👏🏻 you 👏🏻 still 👏🏻 using 👏🏻 polymyxin?

#ASHP19 #SIDPEC

#TLDR How to treat CRE? #ASHP19 #SIDPEC

DO NOT USE POLYMYXIN

Switching speakers, now we have @ErinMcCreary leading us in learning about resistant Pseudomonas. Common mechanisms to "old" antibiotics differs for Pseudomonas. Potential targets for new/combo drugs. #ASHP19 #SIDPEC

Nice summary slide of TOL/TAZ to round out the earlier ones of CAZ/AVI and MER/VAB. #ASHP19 #SIDPEC

Hey Erin, should we be using aminoglycosides or colistin to treat our resistant Pseudomonal infections? #NO. #ASHP19 #SIDPEC

ANOTHER amazing summary slide of new combo IMI/REL. #ASHP19 #SIDPEC

#TLDR how to treat BL resistant Pseudomonas?

Test all 3! TOL/TAZ, CAZ/AVI, IMI/REL #ASHP19 #SIDPEC

Worried about (the cutest acronym ever) CRAb 🦀? Carbapenem-resisant Acinetobacter?

Possibly a role for Eravacycline, but unfortunately no in vivo data. Yet. #ASHP19 #SIDPEC

And possibly some upcoming options for CRAB as well. #Cefiderocol #Durlowhat? #Durlobactam

#ASHP19 #SIDPEC

The beauty of a 1.5 hour CE? The ability to talk about ESBLs! #ASHP19 #SIDPEC

Everyone's favorite table to hate on! 🚦 tables! #ASHP19 #SIDPEC

.....and mechanisms of resistance with the new drugs plugged in. #ASHP19 #SIDPEC

And that's a wrap! #ASHP19 #SIDPEC

No idea how Erin does this on a regular basis! 🤣

Thank you to @ProCEhealth @SIDPharm @ASHPOfficial for this FANTASTIC midday session! And to @OncIDPharmd and @ErinMcCreary for presenting! 👏🏻